Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome

M. A Aloe Spiriti, R. Latagliata, P. Niscola, A. Cortelezzi, M. Francesconi, D. Ferrari, E. Volpe, M. Clavio, A. Grossi, M. Tambone Reyes, P. Musto, M. E. Mitra, A. Azzarà, D. Pagnini, G. D'Arena, A. Spadano, E. Balleari, P. Pecorari, E. Capochiani, E. De BiasiD. Perego, B. Monarca, F. Pisani, G. Scaramella, M. C. Petti

Research output: Contribution to journalArticle

Abstract

This study evaluated the impact of a new epoetin alfa dosing regimen on quality of life (QOL), transfusion requirements, and hemoglobin (Hb) levels in 133 patients with low-risk myelodysplastic syndrome (MDS) and Hb ≤10 g/dl. Epoetin alfa 40,000 IU was given subcutaneously twice weekly; after 4 weeks, the dose could be reduced to 40,000 IU weekly in patients achieving erythroid response. QOL was assessed using the functional assessment of cancer therapy-anemia (FACT-An) questionnaire. FACT-An scores increased on average by 7.5 after 4 weeks and by 8.8 after 8 weeks compared with baseline. FACT-An scores were positively associated with Hb values (r =0.53, P

Original languageEnglish
Pages (from-to)167-176
Number of pages10
JournalAnnals of Hematology
Volume84
Issue number3
DOIs
Publication statusPublished - Mar 2005

    Fingerprint

Keywords

  • Anemia
  • Epoetin
  • Fatigue
  • Myelodysplastic syndrome
  • Quality of life

ASJC Scopus subject areas

  • Hematology

Cite this

Spiriti, M. A. A., Latagliata, R., Niscola, P., Cortelezzi, A., Francesconi, M., Ferrari, D., Volpe, E., Clavio, M., Grossi, A., Reyes, M. T., Musto, P., Mitra, M. E., Azzarà, A., Pagnini, D., D'Arena, G., Spadano, A., Balleari, E., Pecorari, P., Capochiani, E., ... Petti, M. C. (2005). Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Annals of Hematology, 84(3), 167-176. https://doi.org/10.1007/s00277-004-0961-9